| Market Capitalization (Millions $) |
144 |
| Shares
Outstanding (Millions) |
193 |
| Employees |
62 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-187 |
| Cash Flow (TTM) (Millions $) |
-71 |
| Capital Exp. (TTM) (Millions $) |
0 |
Gossamer Bio Inc
Gossamer Bio Inc. is a biopharmaceutical company that focuses on discovering, developing and commercializing therapeutics that address unmet needs in the treatment of various infectious, inflammatory and oncology diseases. It was founded in 2015 by Dr. Faheem Hasnain and Dr. Sheila Gujrathi, both of whom have extensive experience in the pharmaceutical industry and have previously worked together at Receptos, a biopharmaceutical company that was acquired by Celgene in 201
The company is headquartered in San Diego, California, and has a robust pipeline of candidates for various indications. Gossamer Bio has a strong focus on cutting-edge technology and market research to stay ahead of the competition. It has developed and acquired intellectual property rights in various small molecule drugs, proteins, and therapeutics.
Gossamer Bio's pipeline includes candidates that target Type 2 inflammation, COVID-19, and multiple oncology programs. Its lead product candidate, GB001, is a small molecule antagonist of the prostaglandin D2 receptor 2 (DP2) designed to treat eosinophilic asthma and chronic rhinosinusitis with nasal polyps. The company is also developing GB002, an inhaled inhibitor of IL-9, for the treatment of asthma, as well as biologic programs that target Type 2 inflammation.
In response to the COVID-19 pandemic, Gossamer Bio has developed GB004, an antibody drug designed to prevent and treat severe COVID-19 infections. It is a SARS-CoV-2-neutralizing antibody that has been shown to have potent in vitro neutralizing activity against multiple variants of the virus. The company is currently conducting Phase 2 clinical trials to evaluate the safety and efficacy of GB004 as a treatment for COVID-19.
In the oncology space, Gossamer Bio is developing GB1275, an oral CD11b agonist inhibitor that is designed to treat a wide range of solid tumors. GB1275 is currently being tested in Phase 2 clinical trials for various indications. The company is also developing GB2064, a first-in-class oral hypoxia-inducible factor (HIF) inhibitor that is designed to treat a wide range of solid tumors.
In addition to its clinical programs, Gossamer Bio has initiated preclinical research on multiple other programs, including candidates for the treatment of chronic obstructive pulmonary disease, fibrotic disorders, and various oncology programs.
Gossamer Bio has established collaborations with various academic institutions, pharmaceutical companies, and research organizations to further advance its pipeline candidates. The company has secured several rounds of funding from both institutional investors and venture capitalists and has a strong financial position to support its ongoing operations.
In summary, Gossamer Bio Inc. is a biopharmaceutical company that is focused on discovering and developing innovative therapeutics that treat a wide range of infectious, inflammatory, and oncology diseases. With a robust pipeline of candidates and a strong foundation of scientific and technological expertise, Gossamer Bio is poised to emerge as a leading player in the biopharmaceutical industry.
Company Address: 3013 Science Park Road San Diego 92121 CA
Company Phone Number: 684-1300 Stock Exchange / Ticker: NASDAQ GOSS
| GOSS is expected to report next financial results on March 16, 2024. |
|
|
